Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. TWST
TWST logo

TWST Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
46.210
Open
45.850
VWAP
43.92
Vol
1.02M
Mkt Cap
2.87B
Low
42.520
Amount
44.66M
EV/EBITDA(TTM)
--
Total Shares
61.31M
EV
2.67B
EV/OCF(TTM)
--
P/S(TTM)
7.25
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.
Show More

Events Timeline

(ET)
2026-02-17
08:00:00
Twist Bioscience Enters Licensing Agreement with Invenra
select
2026-02-02 (ET)
2026-02-02
16:20:00
Dow Jumps 515.19 Points as Trump Lowers India's Tariff to 18%
select
2026-02-02
12:10:00
Dow Jones Index Rises 0.89% to 49,325.46 Points
select
2026-02-02
10:10:00
Twist Bioscience Shares Rise 12.5% to $46.21
select
2026-02-02
09:00:00
U.S. Stock Futures Weaker, Tech Stocks Under Pressure
select
2026-02-02
07:40:00
Company Expects FY26 Q4 EBITDA Breakeven, Revenue of $435-440 Million
select
2026-02-02
07:30:00
Twist Bioscience Q1 Revenue Reaches $103.7 Million
select

News

Benzinga
2.0
03-01Benzinga
Market Overview: Investment Opportunities and Risks
  • Investment Potential Analysis: Twist Bioscience (NASDAQ:TWST) shows strong performance above $40.00-$41.00, with analysts predicting a target price of $75.00-$80.00, indicating a 60% return potential and reflecting market optimism in the biotech sector.
  • Market Sentiment Assessment: Despite a prevailing fear in the market, analysts suggest this fear could provide a floor for stock prices, indicating that the market may be nearing a bottom, with potential rebounds expected in the coming weeks, particularly in technology and consumer sectors.
  • Jobs and Wage Data: Key employment and wage data will be released this week, and if the data comes in weak, it could prompt the Fed to act sooner than expected, with analysts forecasting a potential rate cut as early as June or late April, which would have significant economic implications.
  • International Market Performance: The outperformance of global stocks compared to U.S. stocks continues, and analysts warn that lacking international exposure may lead to missed alpha opportunities, especially in the current global economic landscape.
Benzinga
9.5
02-24Benzinga
ARK Invest's 2025 Performance Review Highlights Key Stocks
  • Robinhood's Market Performance: Robinhood Markets, Inc. (NASDAQ:HOOD) achieved a 204% gain in 2025, successfully transitioning into a full-service financial hub, with the launch of international brokerage services and a credit card product diversifying its revenue streams and strengthening its asset base.
  • AMD's Market Position: Advanced Micro Devices, Inc. (NASDAQ:AMD) delivered a solid 77% return in 2025, and despite intense competition, its partnerships with major hyperscalers for AI accelerators helped sustain market share gains in the x86 server CPU market, bolstering its valuation.
  • Shopify's Operational Efficiency: Shopify maintained its dominant market position amid a complex consumer spending environment, with ARK highlighting that its focus on operational efficiency allowed it to navigate market challenges and secure a competitive edge.
  • Recursion's Challenges: Recursion Pharmaceuticals (NASDAQ:RXRX) fell 40% in 2025 as it rationalized its portfolio and discontinued several low-activity clinical programs; however, ARK remains confident in the company's long-term objectives despite short-term market scrutiny.
seekingalpha
5.0
02-20seekingalpha
Twist Bioscience Executive Stock Sale Affects Market Sentiment
  • Executive Sell-off Impact: Twist Bioscience's Senior VP of Human Resources, Paula Green, sold over 39,400 shares for nearly $2.1 million, reducing her stake by 24%, which may raise concerns about the company's future prospects among investors.
  • Stock Price Fluctuation: This sale follows a significant 65% increase in the company's stock price this year, particularly a 14% rise on February 2 due to an upward guidance revision for Q1 FY26, indicating that executive sell-offs can negatively affect investor confidence.
  • Market Reaction: Following the disclosure of the stock sale, Twist Bioscience's shares fell approximately 7% in premarket trading, reflecting the market's sensitivity to insider selling and concerns regarding the company's future performance.
  • Stake Changes: After the sale, Green's holdings decreased to about 126,000 shares, suggesting a potential decline in executive confidence in the company's stock, prompting investors to monitor future shareholder dynamics and company performance closely.
seekingalpha
8.5
02-17seekingalpha
Twist Bioscience Acquires Antibody Platform Rights from Invenra
  • Transaction Overview: Twist Bioscience announced a cash-and-stock deal to acquire licensing rights to an antibody discovery platform from Invenra, involving $5 million in cash and $15 million in common stock, indicating the company's strategic expansion in antibody development.
  • Collaboration Model: Under the agreement, Twist and Invenra will jointly serve as co-exclusive providers of Invenra's B-Body bispecific antibody platform, significantly enhancing Twist's existing antibody discovery services and improving its competitive position in the market.
  • Equity Investment: Twist will also purchase preferred stock from existing Invenra shareholders for $13.8 million in common stock, acquiring approximately 6% ownership, which not only strengthens the strategic partnership but also lays the groundwork for future technological integration.
  • Future Outlook: Twist Bioscience targets $435 million to $440 million in revenue for fiscal 2026 while increasing investments in AI-enabled discovery, demonstrating the company's long-term growth potential and ongoing commitment to innovation in the biotechnology sector.
Fool
6.5
02-11Fool
Biotech Sector Faces FDA Turmoil
  • FDA Chaos Impacts Approvals: The biotech sector had a strong performance in 2025, with the XBI index outperforming NVIDIA, yet ongoing chaos at the FDA may lead to longer drug approval cycles, increasing investment risks and affecting industry confidence.
  • Executive Warns of Industry Risks: Former FDA oncology head Richard Pasdur warned at the JP Morgan conference that the breach between political appointees and drug reviewers could lead to inconsistent approval standards, creating uncertainty for biotech companies.
  • Gene Therapy Approval Delays: Regenxbio's expected approval for a Hunter syndrome drug on February 8 is now unlikely due to a tumor found in a patient during clinical trials, indicating stricter FDA oversight on gene therapies and prompting investor caution.
  • Twist Bioscience Shows Recovery: Twist Bioscience reported $104 million in revenue for Q1, despite remaining unprofitable, but reduced cash burn indicates a sustainable growth trend, attracting investor interest amid the biotech downturn.
Benzinga
9.5
02-03Benzinga
Twist Bioscience Reports Strong Q1 Sales, Raises Guidance
  • Strong Sales Performance: Twist Bioscience reported Q1 sales of $103.7 million, a 17% year-over-year increase, surpassing market expectations of $102.72 million, indicating robust market performance and growth potential.
  • Stable Profitability Outlook: The company posted a loss of $0.50 per share, in line with Wall Street expectations, yet management remains focused on achieving profitability with gross margins above 50%, reflecting a healthy financial outlook.
  • Raised Sales Guidance: Twist Bioscience increased its fiscal 2026 sales guidance from $425 million-$435 million to $435 million-$440 million, exceeding the consensus of $431.39 million, demonstrating confidence in future growth.
  • Analyst Rating Upgrades: Barclays analyst raised the price target from $39 to $50, while Evercore ISI analyst increased the target from $42 to $52, reflecting optimistic market sentiment regarding Twist Bioscience's future performance.
Wall Street analysts forecast TWST stock price to rise
5 Analyst Rating
Wall Street analysts forecast TWST stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
39.00
Averages
41.25
High
43.00
Current: 0.000
sliders
Low
39.00
Averages
41.25
High
43.00
Evercore ISI
Outperform
maintain
$42 -> $52
AI Analysis
2026-02-03
Reason
Evercore ISI
Price Target
$42 -> $52
AI Analysis
2026-02-03
maintain
Outperform
Reason
Evercore ISI raised the firm's price target on Twist Bioscience to $52 from $42 and keeps an Outperform rating on the shares. Driven by NGS normalization and AI-driven drug discovery, Twist Bioscience is "set for solid growth into FY26," the analyst tells investors.
Baird
Outperform
upgrade
$33 -> $50
2026-02-03
Reason
Baird
Price Target
$33 -> $50
2026-02-03
upgrade
Outperform
Reason
Baird raised the firm's price target on Twist Bioscience to $50 from $33 and keeps an Outperform rating on the shares. The firm uppdated its model following Q4 results where the company raised its 2026 revenue guidance on broad based momentum.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TWST
Unlock Now

Valuation Metrics

The current forward P/E ratio for Twist Bioscience Corp (TWST.O) is -20.96, compared to its 5-year average forward P/E of -16.05. For a more detailed relative valuation and DCF analysis to assess Twist Bioscience Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-16.05
Current PE
-20.96
Overvalued PE
-6.11
Undervalued PE
-25.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-16.67
Current EV/EBITDA
-32.84
Overvalued EV/EBITDA
-5.77
Undervalued EV/EBITDA
-27.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
11.28
Current PS
4.60
Overvalued PS
22.37
Undervalued PS
0.20

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

bets dips today to buy
Intellectia · 17 candidates
Market Cap: >= 2.00BRegion: USRsi Category: moderatePrice Change Pct: $-6.00 - $-2.00Relative Vol: >= 1List Exchange: XNYS, XNAS, XASEMonth Price Change Pct: $5.00 - $40.00One Week Predict Return: >= 0.0%
Ticker
Name
Market Cap$
top bottom
HRL logo
HRL
Hormel Foods Corp
13.44B
SMCI logo
SMCI
Super Micro Computer Inc
20.15B
TPB logo
TPB
Turning Point Brands Inc
2.43B
CNX logo
CNX
CNX Resources Corp
5.64B
ITT logo
ITT
ITT Inc
17.48B
IPAR logo
IPAR
Interparfums Inc
3.28B
what’s a good buy for day trading
Intellectia · 2418 candidates
Region: USPrice: $2.00 - $200.00Volume: >= 200,000List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
AZN logo
AZN
AstraZeneca PLC
298.35B
PLAG logo
PLAG
Planet Green Holdings Corp
30.35M
AQST logo
AQST
Aquestive Therapeutics Inc
509.36M
CATX logo
CATX
Perspective Therapeutics Inc
351.47M
ASTI logo
ASTI
Ascent Solar Technologies Inc
29.36M
PAVM logo
PAVM
PAVmed Inc
9.16M

Whales Holding TWST

E
EdgePoint Investment Group Inc.
Holding
TWST
+1.71%
3M Return
S
Soleus Capital Management, L.P.
Holding
TWST
-5.11%
3M Return
A
ARK Investment Management LLC
Holding
TWST
-6.27%
3M Return
C
Comprehensive Financial Management LLC
Holding
TWST
-13.64%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Twist Bioscience Corp (TWST) stock price today?

The current price of TWST is 43.02 USD — it has decreased -8.19

What is Twist Bioscience Corp (TWST)'s business?

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.

What is the price predicton of TWST Stock?

Wall Street analysts forecast TWST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TWST is41.25 USD with a low forecast of 39.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Twist Bioscience Corp (TWST)'s revenue for the last quarter?

Twist Bioscience Corp revenue for the last quarter amounts to 103.70M USD, increased 16.89

What is Twist Bioscience Corp (TWST)'s earnings per share (EPS) for the last quarter?

Twist Bioscience Corp. EPS for the last quarter amounts to -0.50 USD, decreased -5.66

How many employees does Twist Bioscience Corp (TWST). have?

Twist Bioscience Corp (TWST) has 979 emplpoyees as of March 12 2026.

What is Twist Bioscience Corp (TWST) market cap?

Today TWST has the market capitalization of 2.87B USD.